The deal, which includes another $200 million in potential payouts, hands the California biotech a candidate in late-stage ...

While early, study results presented at ASH show Tern’s drug could surpass Novartis’ Scemblix and “raise the bar in efficacy” ...

The data and AI algorithms within companion apps can help HCPs provide a diagnosis quicker, allowing them to compare their ...

Dyne is readying a competitor to Sarepta’s Exondys 51. Elsewhere, a pair of obesity drugs showed promise and Kymera’s protein ...

In a head-to-head trial, Lilly’s drug was as effective as Imbruvica at inducing responses and displayed certain safety ...

Casgevy, now a "national priority" drug, helped kids with sickle cell and thalassemia, results which may help toward a label ...

A high-stakes meeting with wide-ranging public health implications again didn’t result in a vote, as members struggled to ...

Data from the "ADEPT-2" study, which analysts had hoped would arrive before year's end, are now expected sometime in 2026.

Weeks after being named head of CDER, Pazdur has submitted paperwork to step down at the end of the month, exacerbating ...

A decades-old way to bridge buyers and sellers on price, contingent value rights have recently seen an uptick in use due to a ...

Phase 3 data could make the Dutch biotech's drug competitive in the increasingly crowded market of hereditary angioedema treatments.

After weakening an endorsement for the hepatitis B vaccine, ACIP began debating the merits of the protocol used to inoculate ...